ArticleJournal of cardiothoracic surgery2026
Cartilage oligomeric matrix protein in pulmonary arterial hypertension associated with lung adenocarcinoma.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePulmonary arterial hypertension (PAH) associated with lung adenocarcinoma (LUAD) is a pathological condition that arises during LUAD progression. Cartilage oligomeric matrix protein (COMP) is an important extracellular matrix (ECM) glycoprotein and may mediate the relationship between PAH and LUAD.
methodsWe collected chest-enhanced CT scans from clinical LUAD patients and screened for PAH using the Pulmonary Artery(PA)/ Aortic(A) ratio. By analyzing the TCGA-LUAD, GSE140797, and VSMCPRG gene sets, we identified gene signatures associated with PAH in LUAD. Additionally, we analyzed pathological samples, serum samples, EdU cell proliferation assays, and measurements of pulmonary artery vascular contractile function.
resultsOur study retrospectively collected relevant data from 421 patients in our department between 2020 and 2025. In the LUAD group, the PA/A ratio ≥ 1 was significantly higher than in both the adenocarcinoma in situ (AIS) group and the Benign nodules group. Immunohistochemical(IHC) analysis of 17 pathological samples revealed significant upregulation of COMP in the LUAD group compared with normal lung tissue. Serum COMP optical density (OD) values were significantly higher in LUAD groups than in control groups, in both humans and mice.EdU assays demonstrated that human pulmonary artery smooth muscle cells (HPASMCs) co-cultured with COMP showed significantly higher proliferation rates than the control group. To assess the effect of COMP on pulmonary artery vasculature, rat and human experiments showed that the contractile force in the COMP group was significantly greater than that in the control group.
conclusionsThese findings suggest that LUAD may be associated with PAH, and that COMP may promote PAH development by enhancing pulmonary artery smooth muscle cell proliferation and vascular contractility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.